MetLife Investment Advisors LLC decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,763 shares of the life sciences company’s stock after selling 511 shares during the period. MetLife Investment Advisors LLC’s holdings in Illumina were worth $15,697,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Highstreet Asset Management Inc. acquired a new position in shares of Illumina in the third quarter worth about $112,000. Ancora Advisors LLC acquired a new position in shares of Illumina in the third quarter worth about $145,000. Sun Life Financial INC boosted its holdings in shares of Illumina by 152.5% in the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after buying an additional 241 shares during the period. SRS Capital Advisors Inc. acquired a new position in shares of Illumina in the third quarter worth about $157,000. Finally, MUFG Americas Holdings Corp acquired a new position in shares of Illumina in the third quarter worth about $183,000. Institutional investors own 88.91% of the company’s stock.
ILMN stock opened at $326.46 on Friday. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24. The company has a market cap of $47.99 billion, a P/E ratio of 81.62, a P/E/G ratio of 2.42 and a beta of 1.09. Illumina, Inc. has a 52 week low of $207.51 and a 52 week high of $372.61.
ILMN has been the subject of several recent analyst reports. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 1st. Cowen raised their target price on shares of Illumina from $315.00 to $400.00 and gave the stock a “positive” rating in a report on Thursday, September 6th. Piper Jaffray Companies raised their target price on shares of Illumina to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, October 2nd. UBS Group initiated coverage on shares of Illumina in a report on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 target price for the company. Finally, ValuEngine cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $330.94.
In related news, Director Robert S. Epstein sold 1,346 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $369.15, for a total transaction of $496,875.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, September 26th. The stock was sold at an average price of $360.81, for a total transaction of $1,190,673.00. Following the sale, the director now owns 388,904 shares of the company’s stock, valued at $140,320,452.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,726 shares of company stock valued at $20,077,106. 0.54% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.com-unik.info/2018/12/16/metlife-investment-advisors-llc-trims-stake-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Article: Compound Interest
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.